| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443714 | European Journal of Cancer | 2014 | 8 Pages |
Abstract
OR occurred in 38% of sunitinib-treated mRCC patients. Sixty-one percent of responses occurred by 12Â weeks of therapy, and responders had favourable pretreatment features and significantly longer survival.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
A.M. Molina, X. Lin, B. Korytowsky, E. Matczak, M.J. Lechuga, R. Wiltshire, R.J. Motzer,